- Home
- AGIO vs LMB Comparison
AGIO vs LMB Comparison
Compare AGIO & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- LMB
- Stock Information
- Founded
- AGIO 2007
- LMB 1901
- Country
- AGIO United States
- LMB United States
- Employees
- AGIO N/A
- LMB N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- LMB Engineering & Construction
- Sector
- AGIO Health Care
- LMB Consumer Discretionary
- Exchange
- AGIO Nasdaq
- LMB Nasdaq
- Market Cap
- AGIO 1.4B
- LMB 1.7B
- IPO Year
- AGIO 2013
- LMB 2014
- Fundamental
- Price
- AGIO $35.00
- LMB $133.48
- Analyst Decision
- AGIO Buy
- LMB Strong Buy
- Analyst Count
- AGIO 6
- LMB 3
- Target Price
- AGIO $57.40
- LMB $140.67
- AVG Volume (30 Days)
- AGIO 840.6K
- LMB 209.0K
- Earning Date
- AGIO 07-31-2025
- LMB 08-05-2025
- Dividend Yield
- AGIO N/A
- LMB N/A
- EPS Growth
- AGIO N/A
- LMB 31.50
- EPS
- AGIO 11.13
- LMB 2.78
- Revenue
- AGIO $40,875,000.00
- LMB $532,913,000.00
- Revenue This Year
- AGIO $18.94
- LMB $22.19
- Revenue Next Year
- AGIO $201.70
- LMB $8.71
- P/E Ratio
- AGIO $3.15
- LMB $48.02
- Revenue Growth
- AGIO 30.57
- LMB 3.62
- 52 Week Low
- AGIO $23.42
- LMB $48.17
- 52 Week High
- AGIO $62.58
- LMB $154.05
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- LMB 46.69
- Support Level
- AGIO $37.09
- LMB $115.10
- Resistance Level
- AGIO $39.12
- LMB $141.18
- Average True Range (ATR)
- AGIO 1.78
- LMB 7.03
- MACD
- AGIO -0.67
- LMB -0.35
- Stochastic Oscillator
- AGIO 9.16
- LMB 52.98
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.